Objective—To determine sensitivity and specificity of
cytologic examination used in a clinical setting.
Animals—216 dogs, 44 cats, 4 horses, 2 ferrets, 1
llama, 1 rat, and 1 mouse.
Procedure—Records were reviewed of cases in
which a cytologic diagnosis was followed by a surgical
biopsy or postmortem examination within 3 days
with subsequent histopathologic diagnosis.
Diagnoses were compared for agreement at various
levels, including complete agreement, partial agreement,
no agreement, or no comparison possible
because of insufficient or incorrect cytologic specimen.
Levels of agreement were compared for different
categories of lesions, including neoplastic, inflammatory,
dysplastic-hyperplastic-other, and normal tissue.
Additionally, levels of agreement for neoplastic
lesions were categorized with regard to cell type,
degree of malignancy, and location. Sensitivity and
specificity of cytologic examination were calculated.
Results—At the level of general agreement (complete
and partial agreement), the sensitivity of cytologic
examination ranged from 33.3 to 66.1%,
depending on the location of the lesion. Cytologic
examination was most accurate when used to diagnose
cutaneous and subcutaneous lesions and least
accurate for diagnosis of liver lesions. Cytologic
examination was most effective in diagnosis of neoplastic
disease and least effective in diagnosis of dysplastic
or hyperplastic conditions.
Conclusions and Clinical Relevance—Cytologic
examination is a valuable diagnostic tool, although our
results indicated lower accuracy than previously
reported. False-negative results (missing a diagnosis)
were far more common than false-positive results
(categorizing a healthy animal as diseased); therefore,
if the clinical index of suspicion is high, cytologic
examination should be repeated or another technique
should be selected to rule out the suspected condition.
(J Am Vet Med Assoc 2003;222:964–967)
Objective—To evaluate responses of cats with vaccine-
associated sarcomas to treatment with surgery
and radiotherapy, with or without adjunctive
Animals—76 cats (78 tumors).
Procedure—Medical records were reviewed. Factors
potentially associated with survival time, time to
recurrence, and time to development of metastases
Results—Following excision, electron beam radiation,
and, in some cases, chemotherapy, 32 (41%)
cats experienced recurrence, and 9 (12%) cats developed
metastases. One- and 2-year survival rates
were 86 and 44%, respectively. Median survival time
from onset of disease was 730 days (range, 30 to
2,014 days). Median disease-free interval was 405
days (range, 30 to 925 days). Cats that underwent
only 1 surgery prior to radiotherapy had a lower recurrence
rate than did cats that underwent > 1 surgery
and had a significantly longer disease-free interval.
Survival time and disease-free interval decreased as
time between surgery and the start of radiotherapy
increased. Cats that developed metastases had significantly
shorter survival times and disease-free
intervals than did cats that did not develop metastases.
Castrated male cats had a significantly shorter
survival time than did spayed female cats. Cats with
larger tumors prior to the first surgery had shorter survival
times. Twenty-six cats received chemotherapy in
addition to surgery and radiotherapy. Whether cats
received chemotherapy was not associated with
recurrence rate, metastasis rate, or survival time.
Conclusions and Clinical Relevance—Results suggest
that excision followed by electron beam irradiation
may be beneficial for treatment of cats with vaccine-
associated sarcomas. Extent of excision prior to
radiotherapy did not seem to be associated with
recurrence rate. (J Am Vet Med Assoc 2001;219:1582–1589)